Research programme: hepatitis C therapeutics - Enanta/Novartis

Drug Profile

Research programme: hepatitis C therapeutics - Enanta/Novartis

Alternative Names: HCV NS3 protein inhibitors - Enanta; Hepatitis C protease inhibitors - Novartis/Enanta

Latest Information Update: 07 Oct 2014

Price : $50

At a glance

  • Originator Enanta Pharmaceuticals; Novartis
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Hepatitis C protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 Oct 2014 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
  • 05 May 2008 Development in this programme is ongoing
  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top